Genetic and Biochemical Studies Establish That the Fungicidal Effect of a Fully Depeptidized Inhibitor of Cryptococcus neoformans Myristoyl-CoA:Protein N-Myristoyltransferase (Nmt) Is Nmt-dependent*

Jennifer K. LodgeDagger §, Emily Jackson-MachelskiDagger , Michelle HigginsDagger , Charles A. McWherter, James A. Sikorski, Balekudru Devadas, and Jeffrey I. GordonDagger parallel

From the Dagger  Department of Molecular Biology and Pharmacology, Washington University School of Medicine, St. Louis, Missouri 63110 and the  Department of Medicinal and Structural Chemistry, G.D. Searle and Company, St. Louis, Missouri 63198

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results & Discussion
References

Cryptococcus neoformans is a fungal pathogen that causes chronic meningitis in 10% of patients with AIDS. Genetic and biochemical studies were conducted to determine whether myristoyl-CoA:protein N-myristoyltransferase (Nmt) is a target for development of a new class of fungicidal drugs. A single copy of a conditional lethal C. neoformans NMT allele was introduced into the fungal genome by homologous recombination. The allele (nmt487D) produces temperature-sensitive myristic acid auxotrophy. This phenotype is due, in part, to under-myristoylation of a cellular ADP ribosylation factor (Arf) and can be rescued by forced expression of human Nmt. Two isogenic strains with identical growth kinetics at 35 °C were used to test the biological effects of an Nmt inhibitor. CPA8 contained a single copy of wild type C. neoformans NMT. HMC1 contained nmt487D plus 10 copies of human NMT. Since a single copy of nmt487D will not support growth at 35 °C, survival of HMC1 depends upon its human Nmt. ALYASKLS-NH2, an inhibitor derived from an Arf, was fully depeptidized: p-[(2-methyl-1-imidazol-1-yl)butyl]phenyl-acetyl was used to represent the GLYA tetrapeptide, whereas SKLS was replaced with a chiral tyrosinol scaffold. Kinetic studies revealed Ki (app) values of 1.8 ± 1 and 9 ± 2.4 µM for purified fungal and human Nmts, respectively. The minimal inhibitory concentration of the compound was 2-fold lower for CPA8 compared with HMC1. A single dose of 100 µM produced a 5-fold greater inhibition of protein synthesis in CPA8 versus HMC1. The strain specificity of these responses indicates that the fungicidal effect was Nmt-dependent. These two strains may be useful for screening chemical libraries for Nmt-based fungicidal compounds with relatively little activity against the human enzyme.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results & Discussion
References

Cryptococcus neoformans is a haploid yeast that causes systemic infection in immunocompromised humans. The organism has tropism for the central nervous system where it produces chronic meningitis. The incidence of infection in patients with acquired immune deficiency syndrome is ~10% (1). New ways of treating cryptococcal meningitis are needed given the limitations of currently available fungicidal and fungistatic agents (e.g. Refs. 2 and 3). An ideal drug target would be a fungal gene product that is expressed under the conditions of infection and that is essential for the viability of the organism. The metabolic pathway and/or substrate specificities of the target protein should be distinguishable from those of the human host. Finally, it would be desirable if the protein is common to many fungal pathogens and is required for their survival.

Studies of C. neoformans pathogenesis have revealed several virulence genes. They encode products involved in capsule formation (CAP59 and CAP64), synthesis of melanin (CNLAC1), and mating (MFalpha ). GPA1 functions as a regulator of each of these functions (4). None of these genes is essential for viability (4-8).

Genetic studies have shown that ADE2 (phosphoribosylaminoimidazole carboxylase) is necessary for the growth of C. neoformans in cerebrospinal fluid (9) and that calcineurin is required for survival at 37 °C (10). A number of other C. neoformans genes have been isolated, but their necessity for growth and/or infection has either not been evaluated by direct genetic tests or the results of such tests have been ambiguous (e.g. Refs. 11-18). One reason for the paucity of such tests is that targeted gene disruption is limited by several factors in C. neoformans. Homologous recombination appears to be inefficient (4-7, 19). There are only a few selectable markers available for conducting such tests (12, 20, 21). Moreover, in the absence of a conditional lethal allele, disruption of an essential gene in this haploid organism will produce death, precluding further analysis of the function of the gene.

The C. neoformans gene encoding myristoyl-CoA:protein N-myristoyltransferase (EC 2.1.3.97) (NMT)1 fulfills many of the criteria for an anti-fungal target. Nmt is a monomeric enzyme that catalyzes the co-translational transfer of myristate, a 14-carbon saturated fatty acid, from CoA to the N-terminal Gly residue of nascent proteins. Cellular N-myristoylproteins have diverse biological functions (22). The enzyme appears to be ubiquitously expressed in eukaryotes, including the two organisms that are the principal causes of systemic fungal infections in immunosuppressed humans, C. neoformans and Candida albicans (23, 24). In vitro studies of purified orthologous Nmts have shown that their acyl-CoA substrate specificities are highly conserved, whereas their peptide substrate specificities are divergent. These differences in peptide recognition have been exploited to develop species-selective peptidomimetic inhibitors (Refs. 25-29; reviewed in Ref. 30). In addition, genetic tests have established that NMT is essential for the growth and viability of both C. neoformans and C. albicans (19, 31).

NMT represents a unique example of an essential C. neoformans gene where a conditional lethal allele has been generated by homologous recombination. This allele was based on a mutant Saccharomyces cerevisiae NMT1 allele (nmt1-451D). nmt1-451D contains a single nucleotide substitution that results in replacement of an absolutely conserved Gly, located 5 residues from the C terminus of the enzyme, with an Asp (32). This substitution reduces the affinity of the enzyme for myristoyl-CoA (33). The analogous mutation in C. neoformans NMT is Gly487 right-arrow Asp (nmt487D). A strain containing several copies of nmt487D, including one at the endogenous locus, was produced (19). It is a myristic acid auxotroph. Withdrawal of myristate produces rapid growth arrest and death within 4 h (19). Virulence studies using isogenic NMT and nmt487D strains and an immunosuppressed rabbit model of cryptococcal meningitis established that genetic attenuation of Nmt activity allows the host to rid itself of an otherwise fatal infection (19).

In the present study, we generated a strain of C. neoformans with a single copy of nmt487D at the endogenous gene locus. This strain was used to correlate cellular protein N-myristoylation with growth and viability. Moreover, strains expressing wild type C. neoformans or human Nmt were employed to show that a species-selective, fully depeptidized inhibitor of the acyltransferase produces fungicidal effects through an Nmt-dependent mechanism.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results & Discussion
References

Strains and Media-- Strains generated during the course of these studies are described in Table I. Two C. neoformans strains, MO49 (ade2, NMT) and CMD2 (ADE2, nmt487D), have been described previously (19, 20). A strain derived from MO49 with an unmapped insertion of ADE2 was named CAP8 in an earlier report (19) but is now renamed CPA8 (Cryptococcus with prototropy for adenine) to avoid confusion with capsule-deficient mutants (34). The following media were used: YPD (1% yeast extract, 2% peptone, 2% glucose); YPD supplemented with 1% Brij 58 (Sigma) and 500 µM myristate or palmitate (NuChek Prep); YNB (yeast nitrogen base; Bio 101); and RPMI 1640 (with glutamine and without bicarbonate; Life Technologies, Inc.).

Expression Vectors-- pCN36-23 was employed for forced expression of a C. neoformans ADP-ribosylation factor (Arf) in C. neoformans. The plasmid contains three components: (i) the C. neoformans GAL7 promoter from pGUST11 (35) containing an NcoI site in place of the NdeI site at the initiator Met codon (engineered by PCR using 5'-TGTTCCGCCGGTGGAAAGAAGCAGG-3' and 5'-GGGCCATGGTCAAGAGGGGATTGAGC-3' as primers and pGUST11 as the template DNA); (ii) the open reading frame of the C. neoformans ARF gene (24), obtained by PCR of genomic DNA from strain MO49 (the PCR reaction contained 5'-GGGGCCATGGGCCTTTCTGTCTCC-3' which incorporates an NcoI site at the initiator ATG, and 5'-CCTTGCGGCCGCGTGCGAAGGTATAAATGGAC-3' which incorporates an NotI site at the 3' end of the coding sequence); and (iii) an NotI fragment from pTelHyg (21) that includes sequences for maintenance in Escherichia coli and a hygromycin resistance cassette. The ARF insert in pCN36-23 was sequenced in its entirety to verify that no unanticipated mutations had been introduced by PCR.

pHS20-57 was used to express human Nmt in C. neoformans. This plasmid consists of five components: (i) a 1.4-kb fragment from C. neoformans NMT that includes transcriptional regulatory elements from its 5'-nontranscribed domain. This fragment spans the region from the HindIII site of pCN25-28 (19) to the ATG of the coding sequence where an NdeI site was engineered by PCR; (ii) a 1.7-kb NdeI/EcoRI fragment from pBB218 which includes the coding sequence of a human Nmt cDNA (36); (iii) an EcoRI/BglII fragment from the polylinker of pSP70 (Promega); (iv) a 2.4-kb BamHI/EcoRI fragment from pCN25-28 containing sequences 3' to the stop codon of C. neoformans NMT (19); and (v) pGEM4Z (Promega) linearized by digestion with HindIII and EcoRI.

Transformation of C. neoformans-- Strains M049 and CMD19 (Table I) were transformed using a Bio-Rad Biolistic PDS-1000/HE particle delivery system and published protocols (19, 20). The diameter of the gold particles was 0.6 µm.

When strain MO49 was transformed with pCN28-14 (nmt487D; 19), cells were selected based on their ability to grow at 24 °C on YNB supplemented with 0.8 g/liter complete synthetic medium without adenine (CSM-ade: Bio 101), 500 µM myristate, 1% Brij 58, and 1 M sorbitol. When strain CMD19 was transformed with pCN36-23 (ARF), cells were selected at 24 °C on YPD containing 200 units/ml hygromycin (Calbiochem). When CMD19 was transformed with either pCN25-28 (C. neoformans NMT) or pHS20-57 (human NMT), cells were selected for their capacity to grow at 35 °C on YPD without supplements. NMT copy number was quantitated by scanning Southern blots of genomic DNA.

Growth Curves-- Fresh colonies were picked from plates into YPD, and the liquid cultures were adjusted to an A595 = 0.1. Aliquots (250 µl) were inoculated into 5 ml of YPD or YPD containing 500 µM myristate and 1% Brij 58. Cultures were then incubated with shaking at 24 or 37 °C. Aliquots (10 µl) were withdrawn at various time points and diluted 1:10 with phosphate-buffered saline (PBS), and the A595 of the sample was determined using a Molecular Devices Thermomax microplate reader. All strains were grown at each condition in triplicate, and each A595 measurement was done in triplicate.

Western Blots of C. neoformans Nmt-- Five-milliliter cultures of C. neoformans strains were grown overnight at 24 °C in YPD supplemented 500 µM myristate and 1% Brij 58. The cells were then pelleted by centrifugation at 900 × g for 10 min at room temperature, washed once in PBS, pelleted once more, and then were resuspended in 0.25 ml of a solution containing 2% SDS, 80 mM Tris, pH 6.8, and 2 mM Pefabloc (Boehringer Mannheim). Following addition of 0.5 ml of zirconia/silica beads (0.5 mm diameter, Biospec Products), the cells were vortexed (3 pulses of 1 min, alternating with 1 min of incubation on ice). The resulting lysates were boiled for 5 min and clarified by centrifugation at 12,000 × g for 5 min. Glycerol (final concentration = 5% v/v), 2-mercaptoethanol (2%), and bromphenol blue (0.002%) were added. Equal amounts of lysate were fractionated by electrophoresis through 10% polyacrylamide gels containing 0.1% SDS (37). The separated proteins were then transferred to Immobilon-P (Millipore) transfer membranes (38). Protein blots were probed with a previously characterized rabbit anti-C. albicans Nmt sera (final dilution = 1:1000-fold in blocking buffer; Refs. 24 and 38). Antigen-antibody complexes were detected using reagents and protocols supplied in the Tropix Western-Light kit.

Arf Protein Mobility Gel Shift Assay-- Fifty-milliliter cultures of C. neoformans strains were grown overnight in YPD, 500 µM myristate, 1% Brij 58 at 24 °C to an A595 approx 2.0-3.0. The cultures were then centrifuged as above, washed twice in 25 ml of PBS, and resuspended in 4-6 ml of YPD. A 1-ml aliquot was added to 10 ml of YPD or YPD, 500 µM myristate, 1% Brij 58. Following a 2-h incubation at 24 or 37 °C, cells were pelleted, washed once in 5 ml of PBS, and resuspended in 0.5 ml of a solution containing 4% SDS and 0.125 M Tris-HCl, pH 6.8. Two volumes of 0.5 mm zirconia/silica beads were added, and cells were disrupted by vortexing as described above. Cleared lysates were prepared and denatured, and the cellular proteins were fractionated using a 16-cm long, 0.75-mm thick, 12% polyacrylamide gel containing 0.1% SDS (37). Separated proteins were transferred to Immobilon-P membranes. The protein blots were subsequently incubated with a previously characterized rabbit anti-S. cerevisiae Arf1p sera (R40, a generous gift of R. Kahn, Emory University) diluted 1:50,000 in PBS containing 1% gelatin, 0.2% Tween 20, and 0.1% sodium azide. Antigen-antibody complexes were detected using the Tropix Western-Light kit.

Synthesis of SC-61213-- Synthesis of this compound was accomplished according to the scheme shown in Fig. 1 and involved reacting the amine (1) with the 2-methylimidazole carboxylic acid (2) in the presence of dicyclohexylcarbodiimide and 1-hydroxybenzotriazole (see Ref. 39 for a description of the seven-step synthesis of compound 1). The resulting product was treated with trifluoroacetic acid at ambient temperature, and the final product (SC-61213) was isolated by reverse phase high pressure liquid chromatography. The 1H NMR and mass spectral data of SC-61213 were consistent with the structure presented in Fig. 1. A stock solution of 40 mM SC-61213 was prepared in sterile deionized water, and aliquots were stored at -20 °C prior to use.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 1.   Synthesis of SC-61213. See "Experimental Procedures."

Kinetic Studies of the Inhibition of Orthologous Nmts by SC-61213-- The effects of SC-61213 on purified C. neoformans, human, and S. cerevisiae Nmts were defined using a previously described two-step enzyme assay (40). The amount of Nmt added to the 110-µl reaction depended upon the species: 50-100 ng of C. neoformans Nmt purified from E. coli (19); 30 ng of a homogeneous preparation of E. coli-derived human Nmt (25); or 3.5 ng of purified recombinant S. cerevisiae Nmt1p (41). The final concentration of [3H]myristoyl-CoA was 0.23 µM. An octapeptide representing the N-terminal sequence of a C. neoformans Arf (GLSVSKLL-NH2) was used as a substrate peptide (final concentration = 10 nM to 2 µM). [3H]Myristoyl-GLSVSKLL-NH2 was purified from the reaction mixture by reverse phase high pressure liquid chromatography using a C18 10-µm µBondapak column (dimensions = 3.9 × 300 mm; Waters Corp.) and a linear gradient from H2O, 0.1% trifluoroacetic acid, 0.05% triethylamine to 100% acetonitrile, 0.1% trifluoroacetic acid. The amount of labeled myristoylpeptide recovered was quantitated with an in-line scintillation counter (42). Peptide Km and Vmax values were determined for each Nmt from double-reciprocal plots. The Km value at each inhibitor concentration and the type of inhibition were determined using double-reciprocal plots (43). Ki values were calculated from Dixon plots (1/v versus [I]; see Ref. 43). All assays were performed at least twice, each time in triplicate.

Antifungal Susceptibility Assays-- The minimal inhibitory concentration of SC-61213 was defined by a broth microdilution anti-fungal test performed according to the protocol described by the National Committee for Clinical Laboratory Standards (NCCLS) tentative standard (44). Briefly, RPMI 1640, buffered to pH 7.0 with MOPS or to pH 5.4 with MES, was introduced together with varying amounts of SC-61213 into each well of a 96-well microtiter plate (Falcon). C. neoformans strains CPA8 and HMC1 were then added to the wells according to the NCCLS protocol. Microtiter plates were incubated at 35 °C without shaking. Forty-eight and 72 h after inoculation, the cells in each well were resuspended by pipetting, and the A550 of the resulting suspension was determined using a Molecular Devices Thermomax plate reader. SC-61213 was tested in a series of 2-fold dilutions over the concentration range 100 to 1.6 µM. Each dilution of the compound was tested on two separate occasions, each time in triplicate. Controls included (i) media without any inoculated C. neoformans to confirm that no contaminants were acquired during the course of the incubation; (ii) media with the isogenic C. neoformans strains but with no drug; and (iii) media containing the strains plus a known fungicidal agent (amphotericin B, 0.25-4 µg/ml).

Protein Synthesis Assays-- To determine the effects of SC-61213 on protein synthesis, cells were grown overnight at 30 °C in YNB, pH 7.0, to an A595 of 0.8. One-milliliter aliquots of the culture were treated with either 3.5 µM cycloheximide or 100 µM SC-61213 for 30 min at 30 °C. [35S]Methionine (100 µCi; 1000 Ci or 37 TBq/mmol) was added to each sample, and the cells were shaken for an additional 30 min at 30 °C. Labeled cells were then harvested by centrifugation, washed once in PBS, and resuspended in 250 µl of 4% SDS, 80 mM Tris, pH 6.8. Cells were disrupted by vortexing three times in the presence of 0.5 ml of zirconia/silica beads as described above. The resulting lysates were then boiled for 5 min and spun at 12,000 × g for 10 min at room temperature. Triplicate aliquots (10 µl each) of the supernatants were spotted onto Whatman Grade 3 filters. Filters were boiled in 10% trichloroacetic acid, washed, and counted in a scintillation counter. All assays were done in triplicate in two independent experiments.

    RESULTS AND DISCUSSION
Top
Abstract
Introduction
Procedures
Results & Discussion
References

Generation of Isogenic Strains Containing Single Copies of NMT or nmt487D and Characterization of Their Growth Phenotypes-- A purified 9.7-kb HindIII fragment from pCN28-14, containing nmt487D and ADE2 as the selectable marker (Fig. 2A), was used to transform a serotype A strain of C. neoformans with an ade2 allele (MO49). Transformants were initially selected on plates lacking adenine and then screened for myristic acid auxotrophy at 24 and 37 °C. Five percent of the adenine prototrophs exhibited auxotrophy for the fatty acid at 37 °C. Southern blotting confirmed that all myristic acid auxotrophs had undergone homologous recombination at the NMT locus. Two-thirds of these auxotrophs had a single copy of nmt487D (e.g. see strain CMD19 in Fig. 2B). Replacement of the endogenous NMT allele was verified by an allele-specific PCR (Ref. 19; data not shown).


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 2.   Southern and Western blot analysis of C. neoformans strains with one or more copies of nmt487D. A, restriction maps of the cloned C. neoformans NMT gene (pCN25-28) and the targeting vector used to generate nmt487D by homologous recombination (pCN28-14). The location of the Gly487 to Asp mutation in nmt487D is indicated by the downward pointing arrow. The sizes of internal EcoRI and HindIII fragments are noted (H, HindIII; E, EcoRI). B, Southern blots of genomic DNAs isolated from the parental NMT, ade2 strain (MO49), an NMT, ADE2 derivative of MO49 (CPA8), and two strains with nmt487D (CMD2, CMD19). C, Western blot containing equivalent amounts of total cellular protein isolated from MO49, CMD2, and CMD19 during log phase growth at 24 °C in YPD/myristate. The blot was probed with rabbit antibodies to purified C. albicans Nmt. These antibodies have been shown previously to cross-react with purified orthologous Nmts (24).

Steady state levels of Nmt were defined in cell lysates prepared from isogenic strains containing 1 copy of wild type NMT (MO49), 1 copy of nmt487D (CMD19), or 10 copies of nmt487D (CMD2). Western blot analysis showed a direct correlation between copy number and cellular levels of the acyltransferase during growth at 24 °C in rich medium (YPD) containing 500 µM myristate (Fig. 2C).

The growth properties of these three isogenic strains were characterized further. In the absence of myristate, the CMD19 strain containing a single copy of nmt487D was unable to grow even at 24 °C (Fig. 3A). In contrast, the isogenic CMD2 strain with 10 copies of nmt487D exhibited only modest growth retardation at 24 °C, although the growth defect worsened progressively as the temperature was raised to 37 °C (Fig. 3A). Addition of 500 µM myristate allowed growth of CMD19 (1 copy) to 30 °C and supported growth of CMD2 (10 copies) to 37 °C. However, in both cases, the rescue by myristate is incomplete when compared with an isogenic NMT strain (Fig. 3A).


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 3.   Effects of nmt487D on growth and morphology. A, comparison of isogenic C. neoformans strains containing NMT or nmt487D. Equivalent numbers of cells from the indicated strains were transferred to each plate, and the plates were incubated at 24-37 °C for 3 days. B, acyl chain length specificity of purified C. neoformans Nmt. Assay conditions are described in Ref. 19 (substrate peptide = GAR[3H]ASVLS-NH2; Ref. 42). Mean values ±1 S.D. are plotted. C, cellular morphology of CPA8 (NMT), CMD2 (10 copies of nmt487D), and CMD19 (1 copy nmt487D) after a 12-h incubation at 24 °C in liquid YPD, 500 µM myristate, 1% Brij 58. All photographs were taken using Nomarski optics at the same magnification. CMD2 and CMD19 cells appear clumped because of their apparent failure to separate after division (e.g. arrows), although the phenotype appears worse in the CMD19 strain.

nmt487D produces a fatty acid auxotrophy that is highly specific for myristate (C14:0). When laurate (C12:0), palmitate (C16:0), or stearate (C18:0) are added to YPD at concentrations equivalent to C14:0, there is no rescue of growth at 24-37 °C for either nmt487D strain (Fig. 3A and data not shown). The selectivity for C14:0 fits with the observed in vitro acyl-CoA chain length specificity of purified C. neoformans Nmt (Fig. 3B).

Brij 58 was included in the medium together with C12:0-C18:0 fatty acids to maintain their solubility in YPD. nmt487D produces sensitivity to this detergent: growth of CMD2 (10 copies of nmt487D) but not MO49 (NMT) is inhibited by 1% Brij 58 (Fig. 3A). We were unable to assess the effects of detergent alone on CMD19 (1 copy of nmt487D) because this strain requires myristate at all temperatures surveyed.

A comparison of the morphologic features of isogenic wild type, CMD19, and CMD2 strains, grown to mid-log phase at 24 °C in YPD containing 500 µM myristate and 1% Brij 58, revealed a second phenotypic characteristic imparted by nmt487D: abberant budding and increased cell size (Fig. 3C). Cells with 1 copy of nmt487D exhibited more severe morphologic abnormalities than cells with 10 copies of the allele.

Levels of Arf N-Myristoylation Correlate with the Growth Phenotype Produced by nmt487D-- Earlier [3H]myristate labeling studies of a wild type strain of C. neoformans had shown that during log phase growth, an Arf was the most prominently labeled cellular N-myristoylprotein (45). An ARF gene was subsequently recovered from C. neoformans and sequenced (24). Co-expression of C. neoformans Nmt and this Arf in E. coli, a bacterium with no endogenous Nmt activity, confirmed that the Arf is a substrate for the acyltransferase (24). N-Myristoylation of Arfs in E. coli changes their electrophoretic mobility during SDS-polyacrylamide gel electrophoresis: acylation produces more rapid migration compared with the corresponding nonmyristoylated recombinant protein (24, 38). This mobility shift can be used to assay levels of protein N-myristoylation in eukaryotic cells. For example, in S. cerevisiae Arf1p and Arf2p are necessary for growth and dependent upon their covalently bound myristoyl moiety for function (46-48). Western blot analysis of cellular lysates prepared from isogenic S. cerevisiae strains containing (i) NMT1 or nmt1-451D (corresponding to C. neoformans nmt487D) and (ii) wild type or null alleles of ARF1 or ARF2 established that a >= 50% reduction in Arf1p/Arf2p acylation is associated with a loss of viability (38).

The gel mobility shift assay was used to define levels of Arf N-myristoylation in isogenic C. neoformans strains containing NMT, 10 copies of nmt487D, and 1 copy of nmt487D. Before doing so, an initial series of Western blots were prepared from E. coli strains that produced the C. neoformans Arf without Nmt (nonmyristoylated Arf standard) or the Arf and C. neoformans Nmt (N-myristoylated Arf standard). Based on Coomassie staining of SDS-polyacrylamide gels containing an equivalent amount of total cell proteins from the two bacterial strains, we were able to conclude that the steady state level of each Arf isoform was equivalent in their respective lysates (data not shown). The Western blots were then probed with rabbit polyclonal antibodies raised against S. cerevisiae Arf1p. The results established that these antibodies recognized the C. neoformans Arf, that the nonmyristoylated and N-myristoylated forms were equally immunoreactive, and that N-myristoylation of the Arf produces an easily recognized increase in its mobility during SDS-polyacrylamide gel electrophoresis (see Arf standards in the left-hand panel of Fig. 4).


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 4.   Effects of nmt487D on Arf N-myristoylation in vivo. Western blots of total cellular proteins were probed with rabbit antibodies raised against purified S. cerevisiae Arf1p. The blots show the relative amounts of N-myristoylated and non-myristoylated isoforms (myr-Arf and Arf) in isogenic C. neoformans strains grown under four different conditions: + and - indicate the presence or absence of 500 µM myristate, 1% Brij 58 in YPD. The blot shown in the left panel contains a set of C. neoformans Arf standards produced in E. coli in the presence or absence of C. neoformans Nmt. The N-myristoylated Arf standard migrates faster than the non-myristoylated standard.

The three C. neoformans strains were grown at 24 °C in YPD/myristate to mid log phase and then incubated for 2 h at either 24 or 37 °C in YPD alone or YPD/myristate. Western blot analysis of cellular proteins indicated that only the N-myristoylated Arf isoform was detectable in the wild type C. neoformans strain under each of the conditions examined (left panel in Fig. 4). The nonmyristoylated Arf isoform only became apparent in the strain with 10 copies of nmt487D after a 2-h incubation at 37 °C without myristate: under these conditions the nonmyristoylated isoform represented ~50% of total immunoreactive Arf (Fig. 4). Cells with a single copy of nmt487D had the greatest reduction in Arf N-myristoylation. At 24 °C, the nonmyristoylated isoform represented ~50% of the total when myristate was included in the medium and >75% 2 h after withdrawal of myristate. At 37 °C, the defects in Arf N-myristoylation worsened (Fig. 4).

These results indicate that nmt487D results in under- myristoylation of a prominent cellular N-myristoylprotein and that the effect occurs in a gene dose-dependent fashion. CMD19 (single copy of nmt487D) was subsequently transformed with the ARF expression vector. The vector contained a complete C. neoformans ARF open reading frame under the control of the galactose-inducible C. neoformans GAL7 promoter and a hygromycin resistance gene (HYGB) under the control of a constitutively expressed actin gene promoter. Transformants were selected at 24 °C on YPD supplemented with myristate and hygromycin. Fig. 5 illustrates the growth phenotype of a transformant (AMC1) which, based on Southern blot analysis, has multiple copies of GAL7-ARF DNA integrated into its genome. In YP-dextrose plus myristate, there is no rescue of growth at 33 °C. In YP-galactose plus myristate, partial rescue of growth was observed at this temperature. Similar results were obtained with other strains containing multiple copies of GAL7/ARF. These findings support the conclusion that this Arf plays a role in defining the growth properties of an nmt487D strain.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 5.   Partial rescue of a nmt487D strain by forced expression of C. neoformans ARF. Growth phenotype of CMD19 without the plasmid and with the ARF plasmid (AMC1). Equal numbers of CMD19 and AMC1 cells were spotted onto media containing either glucose or galactose as the carbon sources (YPD and YP-GAL, respectively), 500 µM myristate and 1% Brij 58. Plates were incubated at 24 or 33 °C for 3 days.

Complementation of nmt487D by Human Nmt-- An in vivo test was designed to examine whether human and C. neoformans Nmts have distinct substrate specificities for C. neoformans proteins. The test consisted of expressing wild type fungal and human Nmts in an nmt487D recipient strain and defining cellular phenotypes under conditions where the activity of the "endogenous" nmt487D enzyme was insufficient to support growth. CMD19 (one copy of nmt487D) was chosen as the recipient strain for transformation with orthologous NMTs because it has a distinctive, easily scored phenotype (strict myristic acid auxotrophy at 24 °C) that is stably maintained (reversion frequency <10-8).

C. neoformans NMT was introduced into CMD19, and myristic acid prototrophs were selected at 35 °C on YPD. The efficiency of transformation averaged 210 colonies/µg DNA (n = 10 experiments). Southern blot analysis of 18 randomly selected myristic acid prototrophs revealed that NMT had been integrated into the CMD19 genome in each case, with an average copy number of 3.

The open reading frame of a human Nmt cDNA was placed under the control of a 1.4-kb fragment representing the region 5' to the initiator ATG codon of C. neoformans NMT. We assumed that this fragment was sufficient to initiate efficient transcription and translation of human Nmt. A 2.4-kb fragment representing the region 3' to the TAA stop codon of C. neoformans NMT was placed downstream of the human Nmt open reading frame. When this human Nmt expression vector was introduced into CMD19, the yield of myristic acid prototrophs was significantly lower than that obtained in parallel experiments with C. neoformans NMT DNA (average difference = 5-fold, n = 9 transformations). Southern blot studies of 19 randomly selected myristic acid prototrophs disclosed a significantly higher average copy number for the human compared to fungal NMT (6 versus 3; p < 0.05).

The growth properties of six strains were then compared in YPD medium. MO49 is the NMT, ade2-containing parent of all of the strains tested. CPA8 was obtained when MO49 was transformed with an ADE2 plasmid (see Table I). CMD19 and CMD2 were generated when MO49 was transformed with nmt487D, ADE2 and, as noted above, have 1 and 10 copies of nmt487D. The other members of the panel were obtained from CMD19 and included CMC2 (2 copies of C. neoformans NMT), CMC1 (10 copies of C. neoformans NMT), HMC2 (2 copies of human NMT), and HMC1 (10 copies of human NMT).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Cryptococcus neoformans strains
Strain names include: CPA, cryptococcus prototrophy for adenine; CMD, cryptococcus mryristoylation-deficient; AMC, Arf myristoylation complemented; HMC, human myristoyltransferase complemented; CMC, cryptococcus myristoyltransferase complemented.

With the exception of CMD19 and CMD2, all strains grew on YPD/agar at 24-37 °C. Growth kinetics were subsequently defined in liquid YPD. No remarkable differences were observed at 24 and 37 °C between the strains containing 1, 2, or 10 copies of C. neoformans NMT (e.g. MO49, CMC2 in Fig. 6A, plus data not shown). The isogenic nmt487D strain complemented with 2 copies of human Nmt DNA showed a slight growth delay at 24 °C and a significant growth defect at 37 °C, analogous to the phenotype of a strain with 10 copies of nmt487D (compare HMC2 and CMD2 in Fig. 6A). Two copies of human NMT only produced partial "correction" of the morphologic abnormalities seen in its CMD19 parent (data not shown). The nmt487D strain with 10 copies of human Nmt DNA grows as well as the strains with wild type C. neoformans NMT (compare HMC1 with MO49 and CMC2 in Fig. 6A) and had normal morphology.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 6.   Effects of forced expression of human Nmt on growth kinetics and Arf N-myristoylation in a C. neoformans strain containing nmt487D. A, strains were incubated at 24 and 37 °C in YPD: MO49 (square ) (single copy C. neoformans NMT), CMD2 (diamond ) (10 copies nmt487D), CMD19 (open circle ) (1 copy nmt487D), CMC2 (triangle ) (1 copy nmt487D/2 copies C. neoformans NMT), HMC1 (black-square) (1 copy nmt487D/10 copies human NMT), and HMC2 (bullet ) (1 copy nmt487D/2 copies human NMT). In separate experiments, CMC1 (1 copy nmt487D/10 copies C. neoformans NMT) and CPA8 (an ADE2 derivative of MO49 with a single copy of C. neoformans NMT) had growth kinetics indistinguishable from those of MO49, HMC1, and CMC2 (not shown). B, myristoylpeptide production by purified human Nmt at various temperatures. Assay conditions were as follows: [3H]myristoyl-CoA = 0.23 µM; substrate peptide (GLSVSKLL-NH2 from the N-terminal sequence of a C. neoformans Arf) = 1 µM (three times its apparent Km); human Nmt = 90 ng/ml; incubation time = 10 min. All assays were performed in triplicate on a least two separate occasions. Mean values ±1 S.D. are plotted. C, assay of Arf N-myristoylation in HMC2 cells.

When GLSVSKLL-NH2, an octapeptide representing the N-terminal sequence of the known C. neoformans Arf, was used as a substrate for purified human Nmt, acylpeptide production was 6.5-fold greater at 37 °C compared with 24 °C (Fig. 6B). When grown in YPD alone, the strain with 2 copies of human NMT (HMC2) produced no improvement in the extent of Arf myristoylation at 24 °C compared with its CMD19 parent (compare Fig. 6C and Fig. 4). However, at 37 °C, human Nmt produced a clear improvement in the extent of Arf myristoylation (50% versus <25%; Fig. 6C and Fig. 4). This finding is consistent with the activity profile of purified human Nmt at 24 and 37 °C.

CMD19 shows impaired growth at 24 °C in YPD. HMC2 shows "normal" growth at 24 °C compared with the wild type MO49 parent, even though the extent of Arf myristoylation in HMC2 is equivalent to that in CMD19. Together, these findings suggest that the extent of N-myristoylation of proteins other than just Arf defines the growth properties at 24 °C of strain HMC2. Our results also imply that human and C. neoformans Nmts have overlapping yet distinct substrate specificities in vivo and that C. neoformans produces one or more essential fungal proteins that cannot be adequately acylated by the human Nmt produced in HMC2.

Use of Isogenic Strains Expressing Human or C. neoformans Nmt to Identify an Nmt-dependent Fungicidal Inhibitor of the Enzyme-- Isogenic strains of C. neoformans expressing wild type fungal or human Nmt can be used to establish whether an in vitro inhibitor of the purified acyltransferase with anti-fungal properties exerts its growth inhibitory effect through in vivo inhibition of the enzyme. Specifically, if an Nmt inhibitor is selective for the fungal compared to human enzyme in vitro, and if that compound also produces a greater degree of inhibition of growth of a fungal Nmt-producing, compared to human Nmt-producing strain, then an Nmt-dependent mechanism for its biological effect can be invoked.

In Vitro Characterization of a Fully Depeptidized Inhibitor of C. neoformans and Human Nmts-- Nmt has an ordered reaction mechanism: the apoenzyme first binds myristoyl-CoA, forming a binary Nmt:myristoyl-CoA complex; peptide then binds, forming a ternary complex; this is followed by catalysis and release of the CoA and myristoylpeptide products (41, 49-51). As noted in the Introduction, the acyl-CoA substrate specificities of orthologous Nmts are highly conserved (30, 52), whereas their peptide substrate specificities are somewhat different.

We have recently identified potent and selective peptidomimetic inhibitors of C. albicans Nmt (25-27, 29, 30, 52, 53). As with C. neoformans, Arfs are the most prominent C. albicans N-myristoylproteins labeled with [3H]myristate during log phase growth (45). Alanine scanning mutagenesis of an octapeptide derived from the N-terminal sequence of an Arf (GLYASKLS-NH2) revealed that Gly1, Ser5, and Lys6 play the most important role in recognition by the peptide binding site of C. albicans Nmt (28). Substitution of Ala for Gly1 yielded an inhibitor (ALYASKLS-NH2) that was competitive for peptide and noncompetitive for myristoyl-CoA. Replacement of the ALYA tetrapeptide with an 11-aminoundecanoyl group and replacement of the C-terminal Leu-Ser with N-cyclohexylethyl lysinamide moiety produced a dipeptide inhibitor that was more potent than the starting octapeptide inhibitor (28). Increased potency and selectivity for C. albicans versus human Nmt was obtained by substituting a 2-methylimidazole for the N-terminal glycyl amine and rigidifying the flexible undecanoyl chain with a 4-substituted phenylacetyl group. This compound (SC-58272) is a competitive inhibitor (Ki = 30 nM using GNAASARR-NH2 as the peptide substrate) and has 250-fold selectivity for the C. albicans enzyme (27). Unfortunately, it produces no growth inhibition when added to log phase cultures of C. albicans or C. neoformans, even at concentrations up to 100 µM (Ref. 38 plus data not shown).

The Ser-Lys dipeptide that remains in SC-58272 is a potential site for cleavage by cellular proteases and may contribute to the lack of biological activity in the compound. Therefore, we synthesized a derivative (SC-61213) that lacks any peptide binds (see Fig. 1).

The p-[(2-methyl-1-imidazol-1-yl)butyl]phenylacetyl moiety present in SC-58272 was retained in SC-61213 and used to represent the N-terminal ALYA tetrapeptide of the parental ALYASKLS-NH2 inhibitor. The C-terminal SKLS was represented in SC-61213 by a chiral tyrosinol scaffold. The imidazole group provided a mimic for the essential N-terminal amino recognition element in Ala1 of ALYASKLS-NH2. The critical Ser5 hydroxyl was retained in the form of an alcohol, and the important epsilon -amino group of Lys6 was represented in the form of a 3-(gamma -aminobutyl) side chain. The hydrophobic interactions provided by Leu7 were provided by the aromatic 4-cyclohexylethyl ether moiety of SC-61213.

A discontinuous Nmt assay was used to define the effects of SC-61213 on purified C. neoformans Nmt. GLSVSKLL-NH2, representing the N-terminal sequence of C. neoformans Arf, was used as the substrate. In the absence of inhibitor, double-reciprocal plots revealed a Km for the octapeptide of 0.6 ± 0.2 µM and and a Vmax of 16,000 ± 1700 pmol myristoylpeptide/min/mg enzyme. Double-reciprocal plot analysis of C. neoformans Nmt activity at different concentrations of SC-61213 suggested a noncompetitive type of inhibition (Fig. 7A). Secondary (Dixon) plots were most consistent with noncompetitive or mixed type inhibition and yielded an apparent Ki of 1.8 ± 1 µM (Fig. 7B).


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 7.   Kinetic analysis of the inhibition of purified orthologous Nmts by SC-61213. The panels on the left (A, C, and E) represent plots of 1/v versus 1/[substrate peptide] in the presence of the different fixed concentrations of the inhibitor SC-61213. Panels on the right (B, D, and F) are secondary Dixon plots appropriate for the pattern of inhibition revealed by the preceding double-reciprocal plots.

GLSVSKLL-NH2 is also a substrate for human Nmt (Km = 0.35 ± 0.15 µM, Vmax = 4400 ± 700 pmol/min/mg) and therefore was used to assess the effects of SC-61213 on the human enzyme. In contrast to C. neoformans Nmt, double-reciprocal plot analysis suggested an uncompetitive type of inhibition (Fig. 7C). Dixon plots revealed an apparent Ki of 9 ± 2.4 µM (Fig. 7D). When the octapeptide was used as a substrate for S. cerevisiae Nmt1p (Km = 22.5 ± 1.1 nM, Vmax = 22,000 ± 2800 pmol/min/mg), a similar uncompetitive type of inhibition was observed (Ki = 4.3 ± 1.1 µM; Fig. 7, E and F).

These studies establish that an octapeptide substrate containing seven peptide bonds and eight chiral centers can be reduced to a nonpeptide inhibitor with one chiral center that is ~5-fold selective for C. neoformans versus human Nmt. The kinetic data suggest that the mode of interaction of the inhibitor with C. neoformans Nmt is different from its interaction with human or S. cerevisiae Nmts. Multiple sequence alignments of the six known orthologous Nmts have disclosed that the 416-529 amino acid enzymes contain 105 absolutely conserved resides that are widely distributed throughout the primary structure (33). When compared with the other Nmts, the C. neoformans enzyme has a unique 22-39-residue insert in its C-terminal third. The inserted sequence begins with three prolines. It remains to be established whether this insert contributes to the enzyme's apparently distinctive interaction with SC-61213.

Characterization of the Biological Effects of SC-61213-- CPA8 (NMT) and HMC1 (nmt487D plus 10 copies of human NMT) were chosen to test whether SC-61213 has any anti-fungal activity. These isogenic myristic acid prototrophs have similar growth kinetics at 35 °C in standard liquid medium (Fig. 8A) and, based on Western blot analysis, have similar steady state levels of Nmt (data not shown). At this temperature, a single copy of nmt487D will not support growth (see above), so growth and survival of HMC1 cells depends upon their human Nmt. SC-61213 is selective for the fungal compared with human enzyme in vitro. Therefore, a greater degree of inhibition of CPA8 compared with HMC1 cell growth would indicate an Nmt-dependent mechanism for its biological effects.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 8.   SC-61213 selectively inhibits growth of C. neoformans strains producing wild type C. neoformans versus human Nmt. A, equal numbers of CPA8 (1 copy of C. neoformans NMT) and HMC1 (1 copy nmt487D/10 copies human NMT) cells were incubated in RMPI 1640 medium, pH 5.4, at 35 °C in the presence or absence of a single dose of SC-61213 (50 µM) administered at time 0. square , CPA8 without inhibitor; open circle , CPA8 + SC-61213; black-square, HMC1 without inhibitor; square , HMC1 + SC-61213. At this concentration, SC-61213 produces complete growth inhibition in the case of CPA8 but only partial inhibition in the case of HMC1. Mean values ±1 S.D. are plotted. Similar results were seen when yeast nitrogen base was used as the medium (data not shown). B and C, inhibition of protein synthesis by SC-61213. B, CPA8 cells were pretreated for 30 min at 30 °C with either SC-61213 (100 µM) or cycloheximide (3.5 µM) and then were pulse- labeled with [35S]methionine for an additional 30 min. [35S]Methionine incorporation into trichloroacetic acid-precipitable total cellular proteins was measured. Mean values ±1 S.D. are plotted. C, comparison of the degree of inhibition of protein synthesis observed 30 min after 100 µM SC-61213 was added to parallel cultures containing equal numbers of CPA8 or HMC1. The graph shows the percentage of [35S]methionine incorporated into total protein in treated relative to untreated cells from each strain. There were no significant differences in protein synthesis between CPA8 and HMC1 cells not treated with drug or when they were incubated with cycloheximide alone (data not shown).

We examined the effects of two-fold serial dilutions of the SC-61213 (1.6-100 µM) on growth and survival of the CPA8 and HMC1 strains. A single dose of each concentration of the compound was added to logarithmically growing cells. Cells were then incubated at 35 °C in standard medium at pH 5.4 or 7.0, and the A550 was defined 48 and 72 h later. SC-61213 inhibited growth in a strain-dependent manner (Fig. 8A). The minimal inhibitory concentration was 2-fold greater for HMC1 compared with CPA8 at pH 5.4 (80 versus 45 µM at 48 h; 82 versus 42 µM at 72 h). This 2-fold difference was observed in two independent experiments, each done in triplicate. At pH 7.0, the difference in minimal inhibitory concentration between strains was less pronounced (e.g. 45 versus 31 µM at 48 h).

To determine whether SC-61213 was fungicidal versus fungistatic, logarithmically growing CPA8 cells (106 colony-forming units/ml) were treated with a single dose of the compound (final concentration = 100 µM in YNB at pH 7.0). The number of colony forming units was defined 24, 48, and 72 h later. After 24 h, no viable cells were detectable (data not shown). The effect could not be simply attributed to cell lysis; loss of viability was not accompanied by a change in A595 of the culture or a demonstrable reduction in cell number (defined using a hemocytometer). The fungicidal effect of the single dose of SC-61213 was sustained for 72 h. Untreated control cells continued to grow during this period.

An Arf gel shift assay, performed on CPA8 cell lysates harvested 2 h after administration of SC-61213 (100 µM), failed to detect any non-myristoylated Arf (data not shown). Since a protein de-myristoylation activity has not been found in eukaryotes (e.g. Ref. 54), production of non-myristoylated Arf should be dependent upon new protein synthesis. It is possible that the failure to detect non-myristoylated Arf in SC-61213-treated CPA8 cells was due to rapid inhibition of translation. To test this hypothesis, logarithmically growing CPA8 cells were treated with 100 µM SC-61213 for 30 min and then pulse-labeled for 30 min with [35S]methionine. A 98% inhibition of protein synthesis was observed (Fig. 8B). The magnitude of this inhibition was similar to that produced by a standard dose of cycloheximide (3.5 µM; see Fig. 8B). A single 100 µM dose of SC-61213 produced 5-fold less attenuation of protein synthesis in HMC1 compared with CPA8 (p < 0.01; Fig. 8C).

The mechanism that underlies this inhibition of protein synthesis remains to be elucidated. It is interesting to note that in S. cerevisiae, polypeptide elongation factor-1alpha (55, 56) is a likely substrate for Nmt1p (N-terminal sequence = GKEKSHIN). The observed inhibition of protein synthesis by SC-61213 could reflect under-myristoylation of an orthologous C. neoformans protein which normally has a rapid turnover time or a perturbation in the interactions of Nmt with other ribosomal proteins (57).

Prospectus-- Taken together, our results support the conclusion that the fungicidal effects of SC-61213 involve Nmt. A similar dose of SC-61213 has fungicidal activity against C. albicans Nmt (39), an observation that lends additional support for Nmt as a legitimate target for development of fungicidal drugs. Our isogenic C. neoformans strains, containing wild type C. neoformans or human Nmt, may prove useful for high throughput screens of large chemical or natural product libraries that seek to identify Nmt-based fungistatic or fungicidal compounds with relatively little activity against the human acyltransferase.

Finally, the reagents developed during the course of this study may also be generally useful for genetic manipulations of C. neoformans. NMT is a good selectable marker; the phenotype produced by nmt487D is distinctive (pronounced temperature-sensitive myristic acid auxotrophy) and stable (reversion frequency <10-8). By using human as opposed to C. neoformans NMT as the selectable marker for transformation of CMD19, it should be possible to increase the copy number of integrated gene products. This approach of varying copy number by using orthologs may be applicable to other genes that are being employed as selectable markers in C. neoformans or other fungal pathogens.

    ACKNOWLEDGEMENTS

We thank Dena Toffaletti, John Perfect, and Joe Heitman (all at Duke University) as well as Dwight Towler (Washington University) for their helpful suggestions and assistance.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant AI38200 and Monsanto Co.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Present address: Edward A. Doisy Dept. of Biochemistry and Molecular Biology, St. Louis University School of Medicine, St. Louis, MO 63104.

parallel To whom correspondence should be addressed: Dept. of Molecular Biology and Pharmacology, Box 8103, Washington University School of Medicine, 660 South Euclid Ave., St. Louis, MO 63110. Tel.: 314-362-7243; Fax: 314-362-7047; E-mail: jgordon{at}pharmdec.wustl.edu.

1 The abbreviations used are: NMT, gene encoding myristoyl-CoA:protein N-myristoyltransferase; Arf, ADP ribosylation factor; kb, kilobase pair; MES, 4-morpholineethanesulfonic acid; MOPS, 4-morpholinepropanesulfonic acid; PBS, phosphate-buffered saline; PCR, polymerase chain reaction.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results & Discussion
References

  1. Mitchell, T. G., and Perfect, J. R. (1995) Clin. Microbiol. Rev. 8, 515-548[Abstract]
  2. Powderly, W. G., Finkelstein, D. M., Feinberg, J., Frame, P., He, W., van der Horst, C., Koletar, S. L., Eyster, E., Carey, J., Waskin, H., Hooton, T. M., Hyslop, N., Spector, S. A., and Bozzette, S. A. (1995) N. Engl. J. Med. 332, 700-705[Abstract/Free Full Text]
  3. van der Horst, C. M., Saag, M. S., Cloud, G. A., Hamill, R. J., Graybill, J. R., Sobel, J. D., Johnson, P. C., Tuazon, C. U., Kerkering, T., Moskovitz, B. L., Powderly, W. G., Dismukes, W. E., National Institute of Allergy and Infectious Diseases Mycoses Study Group, and AIDS Clinical Trials Group. (1997) N. Engl. J. Med. 337, 15-21[Abstract/Free Full Text]
  4. Alspaugh, J. A., Perfect, J. R., and Heitman, J. (1997) Genes Dev. 11, 3206-3217[Abstract/Free Full Text]
  5. Chang, Y. C., and Kwon-Chung, K. J. (1994) Mol. Cell. Biol. 14, 4912-4919[Abstract]
  6. Chang, Y. C., Penoyer, L. A., and Kwon-Chung, K. J. (1996) Infect. Immun. 64, 1977-1983[Abstract]
  7. Salas, S. D., Bennett, J. E., Kwon-Chung, K. J., Perfect, J. R., and Williamson, P. R. (1996) J. Exp. Med. 184, 377-386[Abstract]
  8. Wickes, B. L., Mayorga, M. E., Edman, U., and Edman, J. C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 7327-7331[Abstract/Free Full Text]
  9. Perfect, J. R., Toffaletti, D. L., and Rude, T. H. (1993) Infect. Immun. 61, 4446-4451[Abstract]
  10. Odom, A., Muir, S., Lim, E., Toffaletti, D. L., Perfect, J., and Heitman, J. (1997) EMBO J. 16, 2576-2589[Abstract/Free Full Text]
  11. Livi, L. L., Edman, U., Schneider, G. P., Greene, P. J., and Santi, D. V. (1994) Gene (Amst.) 150, 221-226[Medline] [Order article via Infotrieve]
  12. Edman, J. C., and Kwon-Chung, K. J. (1990) Mol. Cell. Biol. 10, 4538-4544[Medline] [Order article via Infotrieve]
  13. Sirawaraporn, W., Cao, M., Santi, D. V., and Edman, J. C. (1993) J. Biol. Chem. 268, 8888-8892[Abstract/Free Full Text]
  14. Parker, A. R., Moore, T. D. E., Edman, J. C., Schwab, J. M., and Davisson, V. J. (1994) Gene (Amst.) 145, 135-138[CrossRef][Medline] [Order article via Infotrieve]
  15. Perfect, J. R., Rude, T. H., Penning, L. M., and Johnson, S. A. (1992) Gene (Amst.) 122, 213-217[CrossRef][Medline] [Order article via Infotrieve]
  16. Cox, G. M., Rude, T. H., Dykstra, C. C., and Perfect, J. R. (1995) J. Med. Vet. Mycol. 33, 261-266[Medline] [Order article via Infotrieve]
  17. Spitzer, E. D., and Spitzer, S. G. (1995) Gene (Amst.) 161, 113-117[CrossRef][Medline] [Order article via Infotrieve]
  18. Tolkacheva, A., McNamara, P., Piekarz, E., and Courchesne, W. (1994) Infect. Immun. 62, 2849-2856[Abstract]
  19. Lodge, J. K., Jackson-Machelski, E., Toffaletti, D. L., Perfect, J. R., and Gordon, J. I. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 12008-12012[Abstract/Free Full Text]
  20. Toffaletti, D. L., Rude, T. H., Johnston, S. A., Durack, D. T., and Perfect, J. T. (1993) J. Bacteriol. 175, 1405-1411[Abstract]
  21. Cox, G. M., Toffaletti, D. L., and Perfect, J. R. (1996) J. Med. Vet. Mycol. 34, 385-391[Medline] [Order article via Infotrieve]
  22. Bhatnagar, R. S., and Gordon, J. I. (1997) Trends Cell Biol. 7, 14-20[CrossRef]
  23. Weston, S. A., Camble, R., Colls, J., Rosenbrock, G., Taylor, I., Egerton, M., Tucker, A. D., Tunncliffe, A., Mistry, A., Mancia, F., de la Fortelle, E., Irwin, J., Bricogne, G., and Pauptit, R. A. (1998) Nat. Struct. Biol. 5, 213-221[Medline] [Order article via Infotrieve]
  24. Lodge, J. K., Johnson, R. L., Weinberg, R. A., and Gordon, J. I. (1994) J. Biol. Chem. 269, 2996-3009[Abstract/Free Full Text]
  25. Devadas, B., Zupec, M. E., Freeman, S. K., Brown, D. L., Nagarajan, S., Sikorski, J. A., McWherter, C. A., Getman, D. P., and Gordon, J. I. (1995) J. Med. Chem. 38, 1837-1840[Medline] [Order article via Infotrieve]
  26. Devadas, B., Freeman, S. K., McWherter, C. A., Kuneman, D. W., Vinjamoori, D. V., and Sikorski, J. A. (1996) Bioorg. Med. Chem. Lett. 6, 1977-1982[CrossRef]
  27. Devadas, B., Freeman, S. K., Zupec, M. E., Lu, H.-F., Nagarajan, S. R., Kishore, N. S., Lodge, J. K., Kuneman, D. W., McWherter, C. A., Vinjamoori, D. V., Getman, D. P., Gordon, J. I., and Sikorski, J. A. (1997) J. Med. Chem. 40, 2609-2625[CrossRef][Medline] [Order article via Infotrieve]
  28. McWherter, C. A., Rocque, W. J., Zupec, M. E., Freeman, S. K., Brown, D. L., Devadas, D., Getman, D. P., Sikorski, J. A., and Gordon, J. I. (1997) J. Biol. Chem. 272, 11874-11880[Abstract/Free Full Text]
  29. Nagarajan, S. R., Devadas, B., Zupec, M. E., Freeman, S. K., Brown, D. L., Lu, H.-F., Mehta, P. P., Kishore, N. S., McWherter, C. A., Getman, D. P., Gordon, J. I., and Sikorski, J. A. (1997) J. Med. Chem. 40, 1422-1438[CrossRef][Medline] [Order article via Infotrieve]
  30. Sikorski, J. A., Devadas, B., Zupec, M. E., Freeman, S. K., Brown, D. L., Lu, H.-F., Nagarajan, S., Mehta, P. P., Wade, A. C., Kishore, N. S., Bryant, M. L., Getman, D. P., McWherter, C. A., and Gordon, J. I. (1997) Biopolymers 43, 43-71[CrossRef][Medline] [Order article via Infotrieve]
  31. Weinberg, R. A., McWherter, C. A., Freeman, S. K., Wood, D. C., Gordon, J. I., and Lee, S. C. (1995) Mol. Microbiol. 16, 241-250[Medline] [Order article via Infotrieve]
  32. Duronio, R. J., Rudnick, D. A., Johnson, R. L., Johnson, R. D., and Gordon, J. I. (1991) J. Cell Biol. 113, 1313-1330[Abstract]
  33. Zhang, L., Jackson-Machelski, E., and Gordon, J. I. (1996) J. Biol. Chem. 271, 33131-33140[Abstract/Free Full Text]
  34. Jacobson, E. S., Ayers, D. J., Harrell, A. C., and Nicholas, C. C. (1982) J. Bacteriol. 150, 1292-1296[Medline] [Order article via Infotrieve]
  35. Wickes, B. L., and Edman, J. C. (1995) Mol. Microbiol. 16, 1099-1109[Medline] [Order article via Infotrieve]
  36. Duronio, R. J., Reed, S. I., and Gordon, J. I. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 4129-4133[Abstract]
  37. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
  38. Lodge, J. K., Jackson-Machelski, E., and Gordon, J. I. (1997) Microbiology 143, 357-366[Abstract]
  39. Devadas, B., Freeman, S. K., McWherter, C. A., Kishore, N. S., Lodge, J. K., Jackson-Machelski, E., Gordon, J. I., and Sikorski, J. A. (1998) J. Med. Chem. 41, 996-1000[CrossRef][Medline] [Order article via Infotrieve]
  40. Rudnick, D. A., Duronio, R. J., and Gordon, J. I. (1992) in Lipid Modification of Proteins: A Practical Approach (Hooper, N. M., and Turner, A. J., eds), pp. 37-61, IRL Press at Oxford University Press, Oxford
  41. Bhatnagar, R. S., Schall, O. F., Jackson-Machelski, E., Sikorski, J. A., Devadas, B., Gokel, G. W., and Gordon, J. I. (1997) Biochemistry 36, 6700-6708[CrossRef][Medline] [Order article via Infotrieve]
  42. Kishore, N. S., Lu, T. B., Knoll, L. J., Katoh, A., Rudnick, D. A., Mehta, P. P., Devadas, B., Huhn, M., Atwood, J. L., Adams, S. P., Gokel, G. W., and Gordon, J. I. (1991) J. Biol. Chem. 266, 8835-8855[Abstract/Free Full Text]
  43. Segel, I. H. (1976) Biochemical Calculations: How to Solve Mathematical Problems in General Biochemistry, 2nd Ed., John Wiley & Sons, Inc., New York
  44. National Committee for Clinical Laboratory Standards (1995) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Tentative Standard, Document M 27-T, National Committee for Clinical Laboratory Standards, Villanova, PA
  45. Langner, C. A., Lodge, J. K., Travis, S. J., Caldwell, J. E., Lu, T., Li, Q., Bryant, M. L., Devadas, B., Gokel, G. W., Kobayashi, G. S., and Gordon, J. I. (1992) J. Biol. Chem. 267, 17159-17169[Abstract/Free Full Text]
  46. Stearns, T., Kahn, R. A., Botstein, D., and Hoyt, M. A. (1990) Mol. Cell. Biol. 10, 6690-6699[Medline] [Order article via Infotrieve]
  47. Kahn, R. A., Clark, J., Rulka, C., Stearns, T., Zhang, C. J., Randazzo, P. A., Terui, T., and Cavenagh, M. (1995) J. Biol. Chem. 270, 143-150[Abstract/Free Full Text]
  48. Randazzo, A. R., and Kahn, R. A. (1995) Methods Enzymol. 250, 394-405[Medline] [Order article via Infotrieve]
  49. Rudnick, D. A., McWherter, C. A., Rocque, W. J., Lennon, P. J., Getman, D. P., and Gordon, J. I. (1991) J. Biol. Chem. 266, 9732-9739[Abstract/Free Full Text]
  50. Rocque, W. J., McWherter, C. A., Wood, D. C., and Gordon, J. I. (1993) J. Biol. Chem. 268, 9964-9971[Abstract/Free Full Text]
  51. Bhatnagar, R. S., Jackson-Machelski, E., McWherter, C. A., and Gordon, J. I. (1994) J. Biol. Chem. 269, 11045-11053[Abstract/Free Full Text]
  52. Kishore, N. S., Wood, D. C., Mehta, P. P., Wade, A. C., Lu, T., Gokel, G. W., and Gordon, J. I. (1993) J. Biol. Chem. 268, 4889-4902[Abstract/Free Full Text]
  53. Brown, D. L., Devadas, B., Lu, H.-F., Nagarajan, S., Zupec, M. E., Freeman, S. K., McWherter, C. A., Getman, D. P., and Sikorski, J. A. (1997) Bioorg. & Med. Chem. Lett. 7, 379-382[CrossRef]
  54. Dohlman, H. G., Goldsmith, P., Spiegel, A. M., and Thorner, J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 9688-9692[Abstract]
  55. Nagata, S., Nagashima, K., Tsunetsugu-Yokota, Y., Fujimura, K., Mizazaki, M., and Kaziro, Y. (1984) EMBO J. 3, 1825-1830[Abstract]
  56. Schirmaier, F., and Philippsen, P. (1984) EMBO J. 3, 3311-3315[Abstract]
  57. Glover, C. J., Hartman, K. D., and Felsted, F. L. (1997) J. Biol. Chem. 272, 28680-26689[Abstract/Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.